Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 12Terminated 3Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Multiple Myeloma 49Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Recurrence 10Lymphoma, Mantle-Cell 9Lymphoma, Follicular 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Neoplasms, Plasma Cell 6Myelodysplastic Syndromes 6Lymphoma, B-Cell, Marginal Zone 6Leukemia 6Lymphoma, T-Cell, Peripheral 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Burkitt Lymphoma 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3

Interventions

Cyclophosphamide 24Mycophenolic Acid 15fludarabine phosphate 14fludarabine 13Whole-Body Irradiation 13Tacrolimus 12Rituximab 12Melphalan 12Filgrastim 11Cyclosporine 11Busulfan 11Radiotherapy 10Peripheral Blood Stem Cell Transplantation 10Antilymphocyte Serum 10Methotrexate 9Doxorubicin 9Gemcitabine 8Etoposide 8Brentuximab Vedotin 8Sirolimus 7pembrolizumab 6Vinblastine 6Nivolumab 6Methylprednisolone 6Granulocyte Colony-Stimulating Factor 6Alemtuzumab 6Dacarbazine 5Cytarabine 5Cord Blood Stem Cell Transplantation 5Carmustine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Hodgkin Disease × Lenalidomide × Clear all
NCT02875067 2020-08-14

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

NYU Langone Health

Phase 1/2 Terminated
6 enrolled 5 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT01742793 2020-03-04

RID

Yale University

Phase 1 Terminated
12 enrolled
LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma, Lymphoma, T-Cell

NCT01116154 2010-12-09

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1 Terminated
30 enrolled
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡